Pfizer Trial Backs Paxlovid Dose for High-Risk Children

Published Date: 27 Jun 2026

A post-marketing trial finds the oral antiviral achieves effective blood concentrations in at-risk children aged 6 years or older with mild-to-moderate COVID.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

In patients with prostate cancer, second-generation antiandrogens may worsen fatigue, falls, and cognitive decline.

2.

New imaging probe helps track prostate cancer and possibly treat it before resistance develops

3.

NIH research cuts leave cancer patient facing hard choice

4.

Promising OS at 5 Years With Chemo-Free Combo in Urothelial Cancer

5.

PFS in Multiple Myeloma Is Improved by Daratumumab Added to Standard Therapy.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot